Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye

NCT00063765 | Completed Phase 1

• 2 other identifiers: 03023403-EI-0234
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the safety of a ciliary neurotrophic factor (CNTF) implant placed in the eye to allow the release of CNTF directly on the retina. The results of this study may lead to a larger investigation of CNTF implants to treat retinitis pigmentosa (RP), a progressive degenerative eye disease that begins with loss of peripheral vision and night blindness and often leads to blindness in later life. Currently, there are no effective treatments for RP. Researchers have found, however, that certain proteins, called ciliary neurotrophic factor (CNTF), can partially protect cells in the eye if given directly inside the eye. A major challenge in treating RP is to deliver medicine directly into the eye. One way to ensure that CNTF gets into the eye is to surgically place an implant inside the eye to release the protein. Patients 18 years of age and older with retinitis pigmentosa whose visual acuity is 20/100 or worse may be eligible for this study. Candidates will be screened with a medical history, physical examination, eye examinations, and eye photographs. The eye examination includes measurement of visual acuity and eye pressure, examination of the pupils and eye movements, and examination of the lens and back of the eye. In addition, patients will have the following tests:

• Visual field test: Patients look at a central spot on a white screen and tell the examiner whenever they see a small light appear at other places on the screen.
• Electroretinogram (ERG): Electrodes are taped to the patient's forehead. Special contact lenses are placed on the eyes, similar to normal contact lenses, after the eye has been numbed with drops. The contact lenses sense small electrical signals generated by the retina. The ERG measures the electrical activity of the retina when it is stimulated by light. For the ERG recording, the patient looks inside a large, hollow, dark sphere, and sees flashes of light, first in the dark, and then with a light turned on in the sphere.
• Optical coherence tomography: This test, done with the machine used to examine the eye, measures retinal thickness by producing cross-sectional pictures of the retina. Participants undergo surgery at the NIH Clinical Center in a 30-minute operation to place the implant in one eye. The surgery is done under local anesthetic. Before the procedure, patients are given a steroid injection along side the eye to minimize inflammation after surgery. Following the procedure, patients return for follow-up visits once a month for 6 months. At these visits, several of the exams described above are repeated to evaluate treatment effects and check for adverse side effects. After 6 months, the implant is surgically removed. Post-surgical care for both implant and explant surgeries include examinations the day and week after surgery to examine the wound, a high dose of steroid immediately after surgery, oral antibiotics for 7 days, and eye drops for 1 week to prevent infection and inflammation.

Conditions

Retinitis Pigmentosa

Keywords

NT-501; CNTF; Retinitis Pigmentosa; RP

Interventions

Ciliary Neurotrophic Factor Implant NT-501 DRUG

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• To participate in this study, the participant must understand and sign the protocol's informed consent (if the participant's vision is impaired to the point where it is not possible to read the informed consent document, the informed consent document will be read in its entirety to the participant).
• Paticipant diagnosis consistent with retinitis pigmentosa (RP) characterized by the following features:
• progressive photoreceptor dysfunction an death
• clinical degeneration of the outer retina
• intraretinal 'bone-spicule' pigment
• visual field constriction
• night blindness
• major reduction of both rod and cone electroretinogram (ERG) responses.
• The first two participants have 20/400 vision or worse in the implant (study) eye with the same or better in the fellow eye, while the remainder of the participants will have visual acuity of 20/100 or worse.
• Participant has an ERG less than 2 MV(28-32 Hz flicker)
• Participant with central visual field of 40 degrees diameter or less with the Goldmann V 4e stimulus (independent of a peripheral crescent of any size)
• Participant medically able to undergo ophthalmic surgery.

You may not qualify if:

• Participant less than 18 years of age.
• Participant medically unable to comply with study procedures or follow-up visits.
• Participant has glaucoma.
• Participant is receiving oral or other insulin treatment for diabetes.
• Participant has cataract and it interferes with the assessment of the posterior segment inflammation using a standard slit lamp examination.
• Participant has undergone intra-ocular lens replacement less than 6 months prior to enrollment.
• Participant has participated in any other clinical trial of a drug or device within the last 6 months.
• Participant is on chemotherapy.
• Participant is on ocular medications known to be toxic to the lens, retina, or optic nerve.
• Participant who is pregnant.
• Participant with retinal inflammatory diseases.
• Participant with macula edema
• Participant is considered immunodeficient or has a known history of HIV.

Sponsors & Collaborators

• National Eye Institute (NEI): lead

Study Sites (1)

National Eye Institute (NEI)

Bethesda, Maryland, 20892, United States

Location

Related Publications (4)

• Aebischer P, Schluep M, Deglon N, Joseph JM, Hirt L, Heyd B, Goddard M, Hammang JP, Zurn AD, Kato AC, Regli F, Baetge EE. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med. 1996 Jun;2(6):696-9. doi: 10.1038/nm0696-696.

  PMID: 8640564 BACKGROUND

• Aebischer P, Kato AC. Treatment of amyotrophic lateral sclerosis using a gene therapy approach. Eur Neurol. 1995;35(2):65-8. doi: 10.1159/000117095.

  PMID: 7796839 BACKGROUND

• A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. Clin Neuropharmacol. 1995 Dec;18(6):515-32. doi: 10.1097/00002826-199512000-00004.

  PMID: 8681312 BACKGROUND

• Kauper K, McGovern C, Sherman S, Heatherton P, Rapoza R, Stabila P, Dean B, Lee A, Borges S, Bouchard B, Tao W. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012 Nov 1;53(12):7484-91. doi: 10.1167/iovs.12-9970.

  PMID: 23049090 DERIVED

MeSH Terms

Conditions

Retinitis Pigmentosa

Condition Hierarchy (Ancestors)

Eye Diseases, Hereditary; Eye Diseases; Retinal Dystrophies; Retinal Degeneration; Retinal Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

• Study Type: interventional
• Phase: phase 1
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: July 3, 2003
• First Posted: July 4, 2003
• Study Start: June 1, 2003
• Study Completion: March 1, 2006
• Last Updated: March 4, 2008

Record last verified: 2006-03

Locations

US (1)